Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.